Ganesan Karthikeyan, ESC 2022: Rivaroxaban over vitamin K antagonists for patients with rheumatic heart disease related atrial fibrillation?
Vitamin K antagonists (VKAs) are the standard of care for patients with rheumatic heart disease related atrial fibrillation. Rivaroxaban is an anticoagulant used to treat and prevent blood clots. In this touchCARDIO interview, we speak with Professor Ganesan Karthikeyan (All India Institute of Medical Sciences, New Delhi, India) to discuss the risk factors of stroke in patients with rheumatic heart disease and the potential benefits of rivaroxaban over VKAs.
The abstract entitled ‘INVICTUS – Rivaroxaban versus VKA for rheumatic atrial fibrillation’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What factors influence stroke risk in patients with rheumatic heart disease? (0:25)
- What are the potential advantages of rivaroxaban over vitamin K antagonists (VKAs) for prevention of stroke or systemic embolism in patients with rheumatic valvular heart disease? (2:04)
Disclosures: Ganesan Karthikeyan has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Atrial Fibrillation here and Cardiovascular Disease here
Share this Video
Related Videos In Cardiovascular Disease
Divaka Perera, ACC 2023: Myocardial viability in patients with ischaemic left ventricular dysfunction, the REVIVED-BCIS2 trial
The REVIVED-BCIS2 trial assessed the use of myocardial viability tests in predicting prognosis following revascularization in patients with ischaemic left ventricular dysfunction. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the REVIVED-BCIS2 trial, its findings and the impact these results will likely […]
Divaka Perera, ACC 2023: Myocardial viability tests for guiding the ischaemic left ventricular dysfunction treatment paradigm
Ischaemic left ventricular dysfunction is encountered frequently by physicians. Myocardial viability tests are utilised as a prospective tool that enables prediction of a patient’s recoverability. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the treatment paradigm for ischaemic left ventricular dysfunction and […]
Zsolt Piroth, TCT 2022: The value of post-PCI FFR and intravascular imaging for cardiovascular failure, a FAME 3 substudy
This FAME 3 substudy aimed to define the value of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) and intravascular imaging for cardiovascular failure. In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the substudy of the FAME 3 trial and the implications for clinical practice. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!